Snyder Emily M, Curtis Kathryn M, Nguyen Antoinette T, Tadikonda Ananya, Kortsmit Katherine, Zapata Lauren B, Whiteman Maura K
Division of Reproductive Health, Centers for Disease Control and Prevention, Atlanta, GA, United States; Oak Ridge Institute for Science and Education, Oak Ridge, TN, United States.
Division of Reproductive Health, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Contraception. 2025 Apr 3:110898. doi: 10.1016/j.contraception.2025.110898.
To systematically review literature on whether hormonal contraception following ulipristal acetate (UPA) for emergency contraception decreases the effectiveness of either drug.
We searched multiple databases through December 2022 for studies assessing the interaction between UPA and hormonal contraception. The primary outcome was contraceptive effectiveness, measured by pregnancy rates or proxy measures (e.g., ovarian activity). We extracted and summarized findings from identified studies, assessed risk of bias for each study, and determined certainty of evidence for all outcomes.
Four studies met inclusion criteria; all had low risk of bias. Two studies assessed whether UPA use affected the ability of oral contraceptives (OCs) to inhibit ovulation; no differences were observed in ovarian activity when starting OCs 1 day after UPA compared with starting OCs 1 day after placebo. Two studies assessed whether OC use affected the ability of UPA to delay ovulation; both studies observed higher proportions of ovulation when UPA was followed by OC use versus delayed or no OC use. One study assessed ovulation risk when UPA was taken after missed OCs, followed by immediate versus delayed OC resumption; no ovulations occurred within the first 5 days after UPA administration in either group, but there was greater risk of ovulation beyond 5 days with delayed versus immediate OC resumption.
While there is no evidence that UPA affects the ability of hormonal contraception to inhibit ovulation, hormonal contraception use immediately or soon after UPA may decrease UPA's ability to delay ovulation. The certainty of evidence ranged from moderate to very low.
If a patient desires hormonal contraception after UPA, an interaction can be avoided by delaying initiation or resumption of hormonal contraception. The risk of pregnancy due to decreased UPA effectiveness with immediate hormonal contraception should be balanced against the risk of subsequent pregnancy due to delay or non-start of hormonal contraception.
系统回顾关于醋酸乌利司他(UPA)用于紧急避孕后使用激素避孕是否会降低两种药物有效性的文献。
我们检索了多个数据库,截至2022年12月,查找评估UPA与激素避孕之间相互作用的研究。主要结局是避孕有效性,通过妊娠率或替代指标(如卵巢活动)来衡量。我们从纳入的研究中提取并总结了研究结果,评估了每项研究的偏倚风险,并确定了所有结局的证据确定性。
四项研究符合纳入标准;所有研究的偏倚风险均较低。两项研究评估了使用UPA是否会影响口服避孕药(OCs)抑制排卵的能力;与在服用安慰剂1天后开始服用OCs相比,在服用UPA 1天后开始服用OCs时,卵巢活动未观察到差异。两项研究评估了使用OCs是否会影响UPA延迟排卵的能力;两项研究均观察到,在使用UPA后再使用OCs时,排卵比例高于延迟使用OCs或不使用OCs的情况。一项研究评估了在漏服OCs后服用UPA,随后立即恢复或延迟恢复OCs时的排卵风险;两组在服用UPA后的前5天内均未发生排卵,但延迟恢复OCs组在5天后的排卵风险高于立即恢复OCs组。
虽然没有证据表明UPA会影响激素避孕抑制排卵的能力,但在UPA之后立即或不久后使用激素避孕可能会降低UPA延迟排卵的能力。证据确定性从中度到非常低不等。
如果患者在使用UPA后希望使用激素避孕,可以通过延迟开始或恢复激素避孕来避免相互作用。应权衡因立即使用激素避孕导致UPA有效性降低而怀孕的风险与因延迟或未开始使用激素避孕而导致后续怀孕的风险。